Instil Bio reports Q3 net loss $2.01/share; first patient dosed in Phase 1 trial of AXN-2510

Instil Bio, Inc.

2025-Q3 EPS reported -$9.53

Cash position $83.4M as of Sept 30, 2025, down from $115.1M at Dec 31, 2024; expects runway beyond 2026.
First patient dosed in Phase 1 trial of AXN-2510/IMM2510 monotherapy in advanced solid tumors in October 2025.
R&D expenses $9.1M in Q3 2025 vs $0.6M in Q3 2024; reflecting increased clinical activity.
Net loss per share (GAAP) $2.01 in Q3 2025 vs $3.54 in Q3 2024; non-GAAP net loss $1.75 vs $2.55.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.